Alliancebernstein L.P. Tyme Technologies, Inc. Transaction History

Alliancebernstein L.P.

$278 Billion
Q2 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Jul 30, 2021	SELL	$1.14 - $1.87 $60,533 - $99,297	-53,100 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$0.87 - $1.26 $3,219 - $4,662	-3,700 Reduced 6.51%	53,100 $65,000
Q3 2020 Nov 12, 2020	SELL	$0.93 - $1.35 $18,321 - $26,595	-19,700 Reduced 25.75%	56,800 $56,000
Q2 2020 Aug 13, 2020	BUY	$0.97 - $1.7 $2,910 - $5,100	3,000 Added 4.08%	76,500 $102,000
Q1 2020 May 14, 2020	BUY	$0.9 - $1.95 $4,230 - $9,165	4,700 Added 6.83%	73,500 $81,000
Q2 2019 Aug 14, 2019	BUY	$0.96 - $1.89 $9,504 - $18,711	9,900 Added 16.81%	68,800 $84,000
Q1 2019 May 14, 2019	BUY	$1.76 - $3.73 $61,776 - $130,923	35,100 Added 147.48%	58,900 $104,000
Q4 2018 Feb 13, 2019	BUY	$2.01 - $4.21 $27,536 - $57,677	13,700 Added 135.64%	23,800 $88,000
Q3 2018 Nov 08, 2018	BUY	$2.18 - $3.44 $22,018 - $34,744	10,100 New	10,100 $28,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.